维普期刊资源整合服务平台（V6.5）

21篇 您的检索式：作者名="Degn KB"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211)markedly improves 24h glycemia and alpha-and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes显示文摘	Degn KB Juhl CB Sturis J		0，，05：	1
2	One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide(NN2211)markedly improves 24-h glycemia and alpha-and betacell function and reduces endogenous glucose release in patients with type 2 diabetes显示文摘	Degn KB Juhl CB Sturis J	2004	Diabetes2004，53，5：	1
3	One week's treatment with the long-acting glucagons-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha-and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes显示文摘	Degn KB Juhl CB Sturis J	2004	Diabetes2004，53，5：	1
4	One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglu- tide (NN2211) markedly improves 24- h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes 显示文摘	Degn KB Juhl CB Sturis J	2004	Diabetes2004，53，5：	1
5	One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α-and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes显示文摘	Degn KB	2004	Diabetes2004，53，3：	1
6	Effect of intravenous infusion of exenatide ( synthetic exendin4 ) on glucose-dependent insulin secretion and counterregulation during hypoglycemia 显示文摘	Degn KB Brock B Juhl CB	2004	Diabetes2004，53，9：	1
7	Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose- dependent insulin secretion and counterregulation during hypoglycemia显示文摘	Degn KB Brock B Juhl CB	2004	Diabetes2004，53，9：	1
8	Effect of intravenous infusion of exenatide(synthetic exendin-4)on glucose-dependent insulin secretion and counterregulation during hypoglycemia显示文摘	Degn KB Brock B Juhl CB	2004	Diabetes2004，53，9：	1
9	One week' s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24 h glycemia and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes显示文摘	Degn KB Juhl CB Sturis J	2004	Diabetes2004，53，5：	1
10	One week's treat- ment with the long-acting glucagons-like peptide 1 de- rivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha-and beta-cell function and reduces endogenous glucose release in patients with type 2 dia- betes显示文摘	Degn KB Juhl CB Sturis J	2004	Diabetes2004，53，5：	1
11	One week's treatment with thelong-acting glucagon-like peptide 1 derivative liraglutide(NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patientswith type 2 diabetes 显示文摘	Degn KB Juhl CB Sturis J	2004	Diabetes2004，53，5：	1
12	One weeks treatment with the long-acting glucagan-like peptide 1 derivative liraglutide ( NN2211 ) markedly improves 24h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in oatients with type 2 diabetes显示文摘	Degn KB Juhl CB Sturis J	2004	Diabetes2004，53，5：	1
13	One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211)markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes显示文摘	Degn KB	2004	Diabetes2004，53，：	1
14	One week's treatment with the long-acting glucagons-like peptide 1 derivative liraglutide(NN2211 ) markedly improves 24 h glycemia and alpha-and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes显示文摘	Degn KB Juhl CB Sturis J	2004	Diabetes2004，53，5：	1
15	One week's treatment with the longacting glucagon-like peptide 1 derivative liraglutide (NN2211)markedly improves 24-h glycemia and alpha-and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes显示文摘	Degn KB Juhl CB Sturis J		0，，：	1
16	The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during pro-found insulin deficiency显示文摘	φsterg(a)rd T Degn KB Gall MA		0，，：	1
17	Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia显示文摘	Degn KB Brock B Juhl CB		0，，：	1
18	Effect of intravenous inth- sion of exenatide ( synthetic exendin4) on glucose-dependent in- sulin secretion and eounterregulation during hypoglycemia 显示文摘	Degn KB Brock B Juhl CB	2004	Diabetes2004，53，9：	1
19	One week' s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211 ) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes显示文摘	Degn KB Juhl CB Sturis J	2004	Diabetes2004，53，5：	1
20	Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia显示文摘	Degn KB Brock B Juhl CB	2004	Diabetes2004，53，9：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示